menu
    • menu
    [{"orgOrder":0,"company":"Dechra Pharmaceuticals Manufacturing","sponsor":"Kindred Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor | Adrenergic receptor alpha-2","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Dechra Pharmaceuticals Manufacturing","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Dechra Pharmaceuticals Manufacturing \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Dechra Pharmaceuticals Manufacturing \/ Dechra Pharmaceuticals Manufacturing"}]

    Find Clinical Drug Pipeline Developments & Deals by Dechra Pharmaceuticals Manufacturing

    Menu

    Dechra Pharmaceuticals Manufacturing

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dechra Pharmaceuticals Manufacturing

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Dechra Pharmaceuticals Manufacturing

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Recipient : Kindred Biosciences

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Kindred Biosciences Announces Mirataz® (mirtazapine transdermal ointment) Transaction

                            Details : The company has entered into a transaction for the sale of Mirataz® to Dechra Pharmaceuticals PLC.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $43.0 million

                            March 16, 2020

                            Lead Product(s) : Mirtazapine

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Recipient : Kindred Biosciences

                            Deal Size : $43.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth